Boehringer Ingelheim BioXcellence

Ingelheim am Rhein, Germany
Monoclonal Antibody Bispecific Antibody Recombinant Protein Antibody Fragments Biosimilars Biologics
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (10) ○ EMA GMP ○ MHRA GMP

Quick Facts: Boehringer Ingelheim BioXcellence

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
Ingelheim am Rhein, Germany
Modalities
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Antibody Fragments, Biosimilars, Biologics
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Boehringer Ingelheim BioXcellence

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs no verified data
Sponsorsno verified data
ModalitiesMonoclonal Antibody, Bispecific Antibody, Recombinant Protein, Antibody Fragments, Biosimilars, Biologics
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (6 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (6 modalities)

Recent News 10 articles

news Wed, 20 Au
Boehringer Ingelheim signs gene therapy manufacturing deal with AnGes - European Pharmaceutical Review
news Wed, 20 Au
HGF gene therapy product - Boehringer Ingelheim
news Tue, 20 Ma
2025 capacity update | BioXcellence - Boehringer Ingelheim
news Tue, 09 Ju
Rezon Bio appoints Dr. Ralf Otto as Chief Operating Officer to support next phase of growth and operational expansion - Manufacturing Chemist
news Tue, 01 Ju
Sutro Biopharma collaboration first-in-class cell-free capabilities - Boehringer Ingelheim
news Thu, 21 Au
Boehringer, AnGes sign agreement for drug manufacturing - Pharmaceutical Technology
news Sat, 10 Au
Antibody and Recombinant Protein CDMO Market Analysis and Forecast 2024-2031 - Insightace Analytic
news Sat, 02 Ma
Producing Value with Boehringer Ingelheim BioXcellence™ August 2014 - BioProcess International
news Fri, 27 Ma
CDMO insights 2025 | BioXcellence - Boehringer Ingelheim
news Fri, 05 Ju
Biotechnology expert joins CDMO - European Biotechnology Magazine

Frequently Asked Questions About Boehringer Ingelheim BioXcellence

What is Boehringer Ingelheim BioXcellence's CDMO Signal Score?
Boehringer Ingelheim BioXcellence has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Boehringer Ingelheim BioXcellence for a manufacturing program?
Use the free AI matchmaker to compare Boehringer Ingelheim BioXcellence against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Recombinant Protein CDMOs → Biologics CDMOs →

Similar CDMOs

Mabion S.A.
Konstantynów Łódźki, Poland
Monoclonal Antibody, Recombinant Protein, Biosimilars, Vaccine Antigens, ADC / PDC (analytics & development), Sterile Fill-Finish
EirGenix
Zhubei City, Hsinchu County, Taiwan
Monoclonal Antibody, Bispecific/Polyclonal Antibody, Recombinant Protein, ADC, Biosimilars, Plasmid DNA
Rentschler Biopharma
Laupheim, Germany
Signal Score: 79.9
Monoclonal Antibody, Recombinant Protein
KBI Biopharma
Durham, NC · Boulder, CO
Signal Score: 83.5
Monoclonal Antibody, Recombinant Protein, AAV, Plasmid DNA
Catalent
Bagsværd, Denmark (operating under Novo Holdings)
Signal Score: 76.5
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish